Necroptosis: Modules and molecular switches with therapeutic implications.
Among the various programmed cell death (PCD) pathways, "Necroptosis" has gained much importance as a novel paradigm of cell death. This pathway has emerged as a backup mechanism when physiologically conserved PCD (apoptosis) is non-functional either genetically or pathogenically. The expanding spectrum of necroptosis from physiological development to diverse patho-physiological disorders, including xenobiotics-mediated toxicity has now grabbed the attention worldwide. The efficient role of necroptosis regulators in disease development and management are under constant examination. In fact, few regulators (e.g. MLKL) have already paved their way towards clinical trials and others are in queue. In this review, emphasis has been paid to the various contributing factors and molecular switches that can regulate necroptosis. Here we linked the overview of current knowledge of this enigmatic signaling with magnitude of therapeutics that may underpin the opportunities for novel therapeutic approaches to suppress the pathogenesis of necroptosis-driven disorders.
['Arora|Deepika|D|', 'Sharma|Pradeep Kumar|PK|', 'Siddiqui|Mohammed Haris|MH|', 'Shukla|Yogeshwer|Y|']
D000818:Animals D051033:Apoptosis Inducing Factor D006801:Humans D058990:Molecular Targeted Therapy D009336:Necrosis D015398:Signal Transduction
Necroptosis Therapeutics Programmed cell death Inflammation